These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10431681)

  • 1. Association of mood disturbance and arrhythmia events in patients after cardioverter defibrillator implantation.
    Dunbar SB; Kimble LP; Jenkins LS; Hawthorne M; Dudley W; Slemmons M; Langberg JJ
    Depress Anxiety; 1999; 9(4):163-8. PubMed ID: 10431681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks.
    Pedersen SS; van Domburg RT; Theuns DA; Jordaens L; Erdman RA
    Am Heart J; 2005 Apr; 149(4):664-9. PubMed ID: 15990750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arrhythmia, device interventions and mortality analysis in patients with implanted cardioverter-defibrillator with/without resynchronisation therapy in dilative cardiomyopathy in primary prevention of sudden cardiac death].
    Lelakowski J; Pudło J; Lelakowska-Pieła M; Rydlewska A; Piekarz J; Domaracki D
    Pol Merkur Lekarski; 2016 Apr; 40(238):216-22. PubMed ID: 27137820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients.
    van den Broek KC; Nyklícek I; van der Voort PH; Alings M; Meijer A; Denollet J
    J Am Coll Cardiol; 2009 Aug; 54(6):531-7. PubMed ID: 19643315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.
    Pires LA; Lehmann MH; Steinman RT; Baga JJ; Schuger CD
    J Am Coll Cardiol; 1999 Jan; 33(1):24-32. PubMed ID: 9935004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular tachycardia during follow-up in patients resuscitated from ventricular fibrillation: experience from stored electrograms of implantable cardioverter-defibrillators.
    Rüppel R; Schlüter CA; Boczor S; Meinertz T; Schlüter M; Kuck KH; Cappato R
    J Am Coll Cardiol; 1998 Nov; 32(6):1724-30. PubMed ID: 9822102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of health care utilization in patients receiving implantable cardioverter-defibrillator therapies: An analysis of the managed ventricular pacing trial.
    Rickard J; Whellen D; Sherfesee L; Peterson BJ; Nahey T; Tang AS; Ellenbogen KA; Cheng A
    Heart Rhythm; 2017 Sep; 14(9):1382-1387. PubMed ID: 28385672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance estimates of the extent and heterogeneity of scar tissue in ICD patients with ischemic cardiomyopathy predict ventricular arrhythmia.
    Zeidan-Shwiri T; Yang Y; Lashevsky I; Kadmon E; Kagal D; Dick A; Laish Farkash A; Paul G; Gao D; Shurrab M; Newman D; Wright G; Crystal E
    Heart Rhythm; 2015 Apr; 12(4):802-8. PubMed ID: 25583153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
    Conte G; Sieira J; Ciconte G; de Asmundis C; Chierchia GB; Baltogiannis G; Di Giovanni G; La Meir M; Wellens F; Czapla J; Wauters K; Levinstein M; Saitoh Y; Irfan G; Julià J; Pappaert G; Brugada P
    J Am Coll Cardiol; 2015 Mar; 65(9):879-88. PubMed ID: 25744005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database.
    MacFadden DR; Crystal E; Krahn AD; Mangat I; Healey JS; Dorian P; Birnie D; Simpson CS; Khaykin Y; Pinter A; Nanthakumar K; Calzavara AJ; Austin PC; Tu JV; Lee DS
    Ann Intern Med; 2012 Feb; 156(3):195-203. PubMed ID: 22312139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: A systematic review and meta-analysis of inappropriate shocks and complications.
    Olde Nordkamp LR; Postema PG; Knops RE; van Dijk N; Limpens J; Wilde AA; de Groot JR
    Heart Rhythm; 2016 Feb; 13(2):443-54. PubMed ID: 26385533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Improved Left Ventricular Systolic Function on the Recurrence of Ventricular Arrhythmia in Heart Failure Patients With an Implantable Cardioverter-Defibrillator.
    Kim M; Kim J; Lee JH; Hwang YM; Kim MS; Nam GB; Choi KJ; Kim JJ; Kim YH
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1191-1198. PubMed ID: 27334231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.